Back to About Us

Hans Schikan, Pharm.D.

Vice Chair of the Board

Mr. Schikan is a co-founder of the Company and has been a director since August 2019. Mr. Schikan is the former CEO of Prosensa Holding N.V. (Nasdaq: RNA), a biopharmaceutical company focusing on novel RNA modulating treatments for rare diseases including Duchenne muscular dystrophy. Under his leadership, the company listed on Nasdaq in 2013. Prosensa was acquired by BioMarin in 2015.

He is currently Chairman of Vicore Pharma (STO: VICO) and Microbiotica Ltd, and Supervisory Board Member of Organon N.V. Previously, he served on the boards of Sobi (STO: SOBI), Hansa Biopharma (STO: HNSA), Wilson Therapeutics (STO: WTX) (acquired by Alexion), Therachon (acquired by Pfizer), VectivBio (Nasdaq: VECT) (acquired by IronWood), Asceneuron, InteRNA and Complix. Mr. Schikan has a Pharm.D. degree from Utrecht University.